Clinician-Guided Care
Every treatment plan is developed and monitored by licensed medical professionals to ensure safety, accuracy, and proper dosing.
+
+
.7★
GLP‑1 + GIP microdosing is a low-dose program that uses two natural hormone signals. It’s designed to support appetite control and metabolic balance in a gentler, more gradual way than traditional higher-dose approaches.
GLP‑1 microdosing focuses on one pathway, while GLP‑1 + GIP uses two. Some people choose the dual approach because it can feel more balanced or consistent day to day, while still staying in a micro-dose framework.
Most people look for subtle, steady changes—not dramatic shifts. Common early experiences include improved hunger awareness, fewer “snack cravings,” and feeling satisfied with smaller portions as your routine becomes more consistent.
Microdosing is commonly chosen because it’s a gentler approach. Side effects can still happen, but many people prefer starting with a lower-dose plan that’s designed to feel more manageable and easier to stick with.
It requires a prescription and medical oversight. Even at lower doses, these medications affect digestion and appetite signals, which is why a licensed provider reviews your history and goals before approving any plan.
Yes, our microdosing program uses compounded medications, which are prepared by licensed pharmacies. Compounded medications are not FDA-approved, but they are commonly used when customized dosing or formulations are needed.
Your provider determines whether a compounded option is appropriate.
Microdosing isn’t an all-or-nothing decision. If you’re not noticing meaningful benefits, your provider can reassess your goals and, if appropriate, discuss transitioning into our full GLP-1 + GIP program or other options that may be a better fit.
Important Medication Info:
FDA-approved medications such as Saxenda®, Victoza®, Wegovy®, and Ozempic® are proprietary to Novo Nordisk™, while Mounjaro® and Zepbound™ are products of Eli Lilly and Company™. This website is not affiliated with, endorsed by, or associated with these companies or their products.
Invigor Medical does not supply FDA-approved branded medications. Instead, compounded alternatives may be prescribed when clinically appropriate and legally permissible. These medications are prepared by licensed 503A pharmacies in accordance with the Federal Food, Drug, and Cosmetic Act.
Compounded drugs are not FDA-approved and do not undergo FDA review for safety, effectiveness, or manufacturing quality. They may be prescribed when commercially available products are unsuitable for an individual’s medical needs, but have not been evaluated by the FDA to confirm safety or efficacy for any specific use.
Important Medication Info:
FDA-approved medications such as Saxenda®, Victoza®, Wegovy®, and Ozempic® are proprietary to Novo Nordisk™, while Mounjaro® and Zepbound™ are products of Eli Lilly and Company™. This website is not affiliated with, endorsed by, or associated with these companies or their products.
Invigor Medical does not supply FDA-approved branded medications. Instead, compounded alternatives may be prescribed when clinically appropriate and legally permissible. These medications are prepared by licensed 503A pharmacies in accordance with the Federal Food, Drug, and Cosmetic Act.
Compounded drugs are not FDA-approved and do not undergo FDA review for safety, effectiveness, or manufacturing quality. They may be prescribed when commercially available products are unsuitable for an individual’s medical needs, but have not been evaluated by the FDA to confirm safety or efficacy for any specific use.
Important Safety Information for GLP-1 Treatments
Compounded medications are legally prescribed under federal law but are not FDA-approved and have not undergone FDA review for safety, effectiveness, or manufacturing quality. The GLP-1 treatment available through Invigor Medical is prescribed based on an individualized medical evaluation by a licensed clinician.
WARNING: Risk of Thyroid C-Cell Tumors
In animal studies, GLP-1 receptor agonists have been associated with thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is not known whether these effects occur in humans. Inform your healthcare provider if you experience neck swelling, hoarseness, difficulty swallowing, or shortness of breath. GLP-1 treatments should not be used by individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Do not use GLP-1 treatments if:
Warnings and Precautions:
Pregnancy and Reproductive Health:
GLP-1 medications may cause harm to a fetus and should not be used during pregnancy or when planning to become pregnant. Discontinue at least two months before a planned pregnancy.
Common Side Effects:
Nausea, vomiting, diarrhea, constipation, abdominal discomfort, fatigue, and headache are the most commonly reported side effects.
Drug Interactions:
GLP-1 treatments may slow gastric emptying and affect the absorption of oral medications. Consult your healthcare provider for guidance on medication timing and adjustments.